Servier pairs with Nerviano on TTK-targeting cancer program
This article was originally published in Scrip
Executive Summary
The French pharma company Servier has signed an R&D collaboration and worldwide license agreement with Nerviano Medical Sciences, an Italian oncology-focused R&D company owned by the region of Lombardy. The deal is for first-in-class Nerviano compounds inhibiting the protein kinase TTK/MPS1.